Cellectis
  • About
    Our mission
    Governance
    Partners
  • Science
    Our Genome Engineering Platform
    TALEN® Technology
    In-House Manufacturing
  • Pipeline
    Product Candidates
  • Investors
    IR Overview
    News
    • Press releases
    • Events and Webcasts
    Presentations
    • Corporate presentations
    • Scientific presentations
    • Scientific publications
    Corporate Governance
    • Board of Directors
    • Executive Committee
    • External Auditors
    • Governance Documents
    • General meetings
    Financial Information
    • SEC filings
    • Financial statements
    • Voting Rights & Share Capital
    • Stock information
    Shareholders Services
    • IR Inquiries
    • IR FAQ
  • Careers
    Our culture
    Job opportunities
  • Contact us
LinkedinX FR
› Investors › Scientific publications
  • About
    • Our mission
    • Governance
    • Partners
  • Science
    • Our Genome Engineering Platform
    • TALEN® Technology
    • In-House Manufacturing
  • Pipeline
    • Product Candidates
  • Investors
    • IR Overview
    • News
      • Press releases
      • Events and Webcasts
    • Presentations
      • Corporate presentations
      • Scientific presentations
      • Scientific publications
    • Corporate Governance
      • Board of Directors
      • Executive Committee
      • External Auditors
      • Governance Documents
      • General meetings
    • Financial Information
      • SEC filings
      • Financial statements
      • Voting Rights & Share Capital
      • Stock information
    • Shareholders Services
      • IR Inquiries
      • IR FAQ
  • Careers
    • Our culture
    • Job opportunities
  • Contact us
FR
LinkedinX

Scientific publications

All 2025 2024 2023 2022 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2003 2002
31
May 2023
20:36 E.S.T.

Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies

Beatriz Aranda-Orgilles ; Isabelle Chion-Sotinel ; Jordan Skinner ; Steven Grudman ; Ben Mumford ; Chantel Dixon ; Jorge Postigo Fernandez ; Piril Erler ; Phillipe Duchateau ; Agnes Gouble ; Roman Galetto ; Laurent Poirot
Cancer Immunology Research
Read more
12
May 2023
08:55 E.S.T.

Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy

Shipra Das, Julien Valton, Philippe Duchateau, Laurent Poirot
Frontiers in Immunology
Read more

Media contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US
cellectis

Clinical-stage biotech · Dual-listed on Nasdaq (CLLS) and Euronext Growth (ALCLS).
Paris · New York · Raleigh.

  • ABOUT
    • Our mission
    • Governance
    • Partners
  • SCIENCE
    • In-House Manufacturing
    • PulseAgile Technology
    • TALEN® Technology
    • Understanding Gene Editing
  • PIPELINE
    • Product Candidates
    • BALLI-01 Trial
    • NATHALI-01 Trial
    • Patients
  • INVESTORS
    • Events
    • Corporate presentations
    • Scientific presentations
    • Scientific publications
    • Governance Documents
    • ESG report
    • Shareholders Meetings
    • SEC filings
    • Financial statements
    • Voting Rights & Share Capital
    • Stock information
    • PDMR Notifications
    • IR Inquiries
    • IR FAQ
  • Careers
    • Our culture
    • Job opportunities
© 2026 Cellectis — All rights reserved
  • Legal notice
  • Community Guidelines